Foldax Appoints Gregory D. Casciaro as Chief Executive Officer
Foldax announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday.
First Patients Outside of U.S. Treated with TRIA Biopolymer Surgical Aortic Heart Valve in India Clinical Trial
Foldax announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial of the TRIATM biopolymer surgical aortic heart valve.
TRIA Transcatheter Biopolymer Heart Valve Shows Promise in Pilot Animal Study
Foldax announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio
Foldax Appoints Scott Huennekens to Board of Directors
Foldax Appoints Scott Huennekens to Board of Directors
First Clinical Study on TRIA Biopolymer Heart Valve Shows Excellent One-Year Performance
Publication in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions Found TRIA Aortic Heart Valve Provided Sustained Improvement in Heart Valve Function to One-Year with Good Safety Profile
Foldax Receives Approval for Clinical Trial of TRIA Biopolymer Surgical Aortic Heart Valve in India
Foldax announces that the Drugs Controller General of India (DCGI) has approved initiation of a clinical trial of the TRIA™ biopolymer surgical aortic heart valve.
Foldax Completes Enrollment in Early Feasibility Study for TRIA Biopolymer Surgical Aortic Heart Valve
Foldax®, Inc. announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve.
